Comparison of Diagnostic Efficacy of [Ga]Ga-FAPI-04 and [F]FDG PET/CT for Staging and Restaging of Gastric Cancer
Frontiers in Oncology, ISSN: 2234-943X, Vol: 12, Page: 925100
2022
- 23Citations
- 19Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations23
- Citation Indexes23
- 23
- Captures19
- Readers19
- 19
Article Description
Purpose: This study aimed to compare the potential diagnostic efficacy of gallium68-fibroblast-activation protein inhibitor ([Ga]Ga-FAPI-04) and fluorine18-fluorodeoxyglucose ([F]-FDG) positron emission tomography-computed tomography (PET/CT) for primary tumors, lymph nodes, and distant metastatic lesions of gastric cancer (GC), and to explore the effects of [Ga]Ga-FAPI-04 and [F]-FDG on tumor staging and restaging in GC. Methods: This single-center retrospective study (NCT2100044131) was conducted at the Affiliated Hospital of the Southwest Medical University between June 2020 and December 2021. Images of patients with GC who were pathologically confirmed and underwent contemporaneous [F]-FDG and [Ga]Ga-FAPI-04 PET/CT within 1 week were analyzed. The diagnostic efficacy of [Ga]Ga-FAPI-04 PET/CT and [F]-FDG PET/CT for TNM staging of GC was compared using McNemar test. The maximum standard uptake value (SUVmax) of each lesion in the two imaging types was compared using the Mann-Whitney U test. Results: In total, 25 patients with GC (mean age, 56 ± 12 years) were evaluated. [Ga]Ga-FAPI-04 PET/CT exhibited higher sensitivity compared to [F]-FDG PET/CT for detecting primary tumors (18/19 [94.74%] vs. 13/19 [68.42%], χ2 = 6.866, P < 0.01), lymph node metastasis (75/77 [97.40%] vs. 32/77 [41.56%], χ2 = 2.888, P =0.089), and distant metastases (275/283 [97.17%] vs. 122/283 [43.11%], χ2 = 11.858, P < 0.01). [Ga]Ga-FAPI-04 accumulation was significantly higher than that of [F]FDG in tumors (median SUVmax, 10.28 vs 3.20; U=59.00, P < 0.01), lymph node metastasis metastases (median SUVmax, 9.20 vs 3.15; U=53.50, P < 0.01), and distant metastases (median SUVmax, 8.00 vs 4.20; U=200.00, P < 0.01). Compared to [F]-FDG PET/CT, [Ga]Ga-FAPI-04 PET/CT resulted in new oncological findings in 14/25 patients and corrected tumor staging or restaging in 7/25 patients. Conclusion: Our preliminary results regarding the impact of [Ga]Ga-FAPI-04 PET/CT on tumor staging highlight the potential of this approach for increasing the accuracy of GC diagnosis, which may facilitate treatment decision-making.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85134251304&origin=inward; http://dx.doi.org/10.3389/fonc.2022.925100; http://www.ncbi.nlm.nih.gov/pubmed/35847877; https://www.frontiersin.org/articles/10.3389/fonc.2022.925100/full; https://dx.doi.org/10.3389/fonc.2022.925100; https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.925100/full
Frontiers Media SA
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know